Startup entity

Lunai Bioworks

Company LNAI

Every one of those 1 sits in a single category, product-launch. Of the tracked stories, 1 of 1 also mention AI Antidote Development Model, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 6.6 for that window.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · Lunai Bioworks

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Lunai Bioworks

Every one of those 1 sits in a single category, product-launch. Of the tracked stories, 1 of 1 also mention AI Antidote Development Model, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 6.6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. We currently track 1 Startup story that mention Lunai Bioworks, all published on March 19, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 48 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Lunai Bioworks. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Cycle Completion

    Target completion for the first 3-year development cycle under the new model.

  2. First Milestone

    Anticipated first-round validation of AI-modeled antidote candidates.

  3. Bidding Window

    Expected commencement of bidding for initial U.S. countermeasure contracts.

  4. Consortium Launch

    Lunai Bioworks officially establishes the National Chemical Defense Consortium.

Stories mentioning Lunai Bioworks 1

Launches Positive

Lunai Bioworks Launches AI Consortium for $1.2B U.S. Chemical Defense

Lunai Bioworks (NASDAQ: LNAI) has established the National Chemical Defense Consortium to secure up to $1.2 billion in U.S. government countermeasure contracts. The initiative centers on a proprietary three-year AI-driven model designed to accelerate the development of chemical antidotes.

2 sources

Lunai Bioworks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.